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Abstract
Objective: Testosterone therapy (TTh) may reduce morbidity/mortality in men with adult-onset testosterone
deficiency (TD), though some cardiovascular safety concerns remain. Increased hematocrit (HCT), a recognized
effect of therapy, may be associated with cardiovascular disease and mortality. We examined HCT change (D) in
men prescribed/not prescribed testosterone, and associations with mortality.
Methods: We analyzed data from a prospective registry study with adult-onset TD patients: 353 men given tes-
tosterone undecanoate (TU) and 384 opting against TTh. Change in HCT after 12, 48, 72, and 96 months of TU
and at final assessment was compared (nonparametric tests). The association between baseline HCT, D HCT, and
mortality was studied using logistic and Cox regression.
Results: HCT increased significantly (median change at final assessment: +5.0%) in men on TTh. HCT was higher
( p = 0.021, rank-sum test) in those alive than in those who died, although median values were identical (49.0%).
Baseline HCT and D HCT were inversely associated with mortality after adjustment for age in both logistic and
Cox regression models. Men with final HCT >49.0% (median) suffered lower mortality than men with HCT £49.0%.
Conclusions: A median HCT increase of 5.0% was associated with TTh, mostly within 48 months of commencing
therapy. An increase in HCT (up to 52.0% at final assessment) was independently associated with reduced mor-
tality, indicating current guidelines using a HCT value of 54.0% as a threshold for management change are ap-
propriate until further study.
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Introduction
Adult-onset testosterone deficiency (TD) (also known
as late-onset TD, age-related TD, and functional TD)
describes, after exclusion of primary (testicular) and
secondary (pituitary/hypothalamic) pathology, a com-
bination of low serum testosterone and associated
symptoms that include reduced bone mineral density,
muscular strength, cognition, and sexual dysfunc-
tion.1–3 Prevalence is estimated at 6–12%4,5 with levels
as high as 40% reported in men with type 2 diabetes
(T2DM).6,7 The diagnosis is important as adult-onset
TD is also associated with increased mortality.8 The be-
lief that low serum testosterone is key in the causation
of increased morbidity and mortality is supported by
the finding that testosterone therapy (TTh) results in
significant improvements in associated symptoms in-
cluding sexual function, depression, physical perfor-
mance, anemia, and bone mineral density9 in men
with adult-onset TD as well as reduction in mortality
in men with T2DM.10–13
However, concerns remain regarding the safety of
TTh. Although most studies demonstrate benefit or
no change in cardiovascular disease (CVD), a few
have reported higher CVD in men prescribed
TTh.14–17 An explanation for these discrepant findings
is that the population of men with adult-onset TD is
heterogeneous18; thus, subgroups with different life-
styles, genetic, and environmental factors may influ-
ence clinical outcomes. Hematocrit (HCT) is a
possible candidate in determining outcome as an in-
crease in this variable is the commonest effect of
TTh.19–21 Different guidelines have set varying HCT
percentage thresholds above which they recommend
withholding/discontinuing TTh and/or phlebotomy.
For example, the British Society of Sexual Medicine,4
Endocrine Society,22 American Urological Associa-
tion,23 and European Association of Urology24 have
all adopted a threshold of 54%. The International Soci-
ety for the Study of the Aging Male has adopted an
HCT threshold of 52%,25 whereas the International
Consultation for Sexual Medicine26 has recommended
an even more conservative HCT threshold of just 50%.
HCT levels have been associated with changes in
morbidity and mortality, although findings vary.19 A
meta-analysis of 16 studies has shown that the highest
HCT tertile (>0.463) was associated with increased
CVD compared with the lowest tertile (<0.417).27
Similarly, in the Framingham cohort (of >34 years
follow-up), the highest HCT quintile was associated
with increased CVD as well as all-cause mortality.28
However, the European Prospective Investigation into
Cancer and Nutrition-Netherlands study found no dif-
ference in CVD between the tertile distributions (>0.47
vs. <0.45) in CVD-free individuals.29 In the Scottish
Heart Health Extended Cohort Study, HCT (mean –
SD: 0.4381 – 0.0394) was significantly associated with
CVD events and mortality, although this association
was lost when the analysis was adjusted for the fol-
lowing confounders: lipids, blood pressure (BP), dia-
betes, smoking status, family history of CVD, and
fibrinogen.30
Boffetta et al. suggested that this lack of consensus
may result from a nonlinear relationship between
HCT, CVD, and mortality.31 Thus, a U-shaped rela-
tionship between categories of HCT and mortality
was found in Iranian adults of both genders, with low
and high HCT values associated with increased overall
mortality.31 Locatelli et al. found, after erythropoietin
therapy in patients with end-stage renal disease and
low baseline HCT (0.301 – 0.045), that mortality was
inversely proportional to the increase in HCT, also
suggesting that the association between morbidity/
mortality and HCT is nonlinear.32
The clinical impact of increased HCT during TTh
requires further understanding. In this study, we report
baseline characteristics of the men prescribed/not pre-
scribed TTh and compare changes in HCT (intra- and
intergroup), though our focus is primarily on men pre-
scribed TTh. This is because of the current uncertainty
regarding clinical outcomes associated with change in
HCT after TTh. We studied the relationship between
HCT and all-cause mortality in men on TTh. HCT is
associated with hemoglobin (Hb) level33,34 and
BP,35–37 both of which are predictors of mortality.38–42
Hence, these and other established risk factors such as
waist circumference (WC), HbA1c, total cholesterol
(TC), and triglycerides (TG) at the final assessment
were included (if found to be significantly associated
with mortality) as confounding variables.
Materials and Methods
We describe analysis of an observational prospective
cumulative registry study comprising 737 men diag-
nosed with adult-onset TD in view of a serum total tes-
tosterone (TT) £12.1 nmol/L and symptoms of TD. In
total, 737 men were recruited from 823 men presenting
with urological symptoms and diagnosed with TD,
after exclusion of primary hypogonadism (n = 39) and
Klinefelter syndrome (n = 47) (Fig. 1). All the men
were offered TTh. Testosterone undecanoate (TU)
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1000 mg per 12 weeks after an initial 6-week interval
was commenced in 353 men [median age (IQR): 60.0
(55, 64) years, median follow-up (IQR): 105.0 (78,
141) months] whereas the remaining 384 men [median
age (IQR): 64.0 (60.0, 67.0) years, median follow-up
(IQR): 114.0 (96, 126) months] opted against TTh (un-
treated) due to financial constraints and/or negative
perceptions of TTh (Fig. 1 and Table 1). Data were
gathered regularly (at least 6 monthly) during follow-
up in all men. The German Medical Association’s eth-
ical guidelines for observational studies were followed
and every participant consented to be included and
have their data analyzed after being provided study
details. Ethics committees (Germany and England)
reviewed the study and stated that formal approval
was not required. Institutional review board approval
was received from University Hospitals Birmingham
NHS Foundation Trust.
Study measurements
Serum TT (trough levels) was measured using an im-
munoassay (Abbott Architect). Hb levels were deter-
mined using photometry (CELL DYN Ruby/Abbott)
and HCT was calculated using Microhaematocrit
(Mindray 3000 Plus). HbA1c was measured using a
high-performance liquid chromatography method on
a TOSOH G7 (HLC-723-Series), whereas TC and TG
concentrations were measured using a colorimetric
assay on the Abbott Alinity c-Module (colorimetric
analysis). BP was taken with the patient seated with
his left arm resting at heart level using a sphygmoma-
nometer according to protocol. Systolic and diastolic
Korotkoff sounds were assessed twice to increase preci-
sion. Once all the requirement measurements were
completed, Nebido was administered intramuscularly
and BP was again determined after a few minutes. The
two values were usually the same, but if there was a dif-
ference of <5 mmHg, an average was taken, if there was
a difference of >5 mmHg, a third measurement was
made, and the mean of the closer values was accepted.
WC was measured midway between the upper hip
bone and the uppermost border of the right iliac crest.
Statistical methods
The baseline HCT in the total cohort was not normally
distributed with both skewness ( p < 0.0001) and kurto-
sis ( p < 0.0001) evident, hence nonparametric tests
were carried out when comparing HCT distributions.
Baseline factors in men on TTh and those untreated
were compared using rank-sum and chi square tests.
Change during follow-up in the former group was an-
alyzed through sign-rank tests. Risk factor prevalence
between survivors/nonsurvivors in TTh-treated men
was compared using rank-sum (univariate) and logistic
regression (multivariate) analyses. Cox regression ana-
lyses were used to additionally study the association be-
tween HCT at final assessment (stratified) and survival,
with these data presented as a Kaplan–Meier plot.
Results
Table 1 shows baseline data from both groups: men
commencing (n = 353) and opting against (n = 384)
TTh. Baseline HCT and Hb were significantly
( p < 0.0001) lower in men in the TTh group. Metabolic
indices also differed significantly with those about to
commence TTh having higher baseline HbA1c, BP,
TC, and TG levels, but lower WC (Table 1). No differ-
ence was observed in the frequency of T2DM or smok-
ing status (Table 1 footnote). Table 1 also shows the
differences between data at baseline and final assess-
ment in men prescribed TTh: median change (D) in
HCT (IQR) was 5.0 (3.0, 7.0)% and median D Hb levels
(IQR) were 0.6 (0.3, 0.7) g/dL. Apart from the expected
increase in trough levels of serum TT, significant
FIG. 1. Details of the patient cohort and follow-up.
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improvements in WC, HbA1c, BP (systolic and diastol-
ic), TC, and TG were associated with TTh. In men not
given TTh, median D HCT (IQR) was 0.0 (1.0, 2.0) at
final assessment (however, sign-rank test suggested a
higher HCT at final assessment, p = 0.0003).
Change in HCT at fixed time points
during follow-up
Figure 2 shows median D HCT at 12, 48, 72, and 96
months in men prescribed/not prescribed TTh. There
was a small but significant increase in HCT distribution
(although the median change was 0%) in untreated
men (n = 294) after 96 months compared with baseline,
but not at 12, 48, or 72 months (median D HCT was 0%
at all the time points). In contrast median HCT in-
creased significantly after 12 months in men given
TTh with the median D HCT subsequently increasing.
The median D HCT (+4%) was identical at 48, 72, and
96 months of follow-up. At each time point, D HCT
was greater in the TTh group (rank-sum test) than in
untreated men (Fig. 2).
Association between HCT and all-cause mortality
All-cause mortality was significantly higher ( p <
0.0001, Chi Sq) in men not prescribed TTh [74/384
men (19.3%)] than in men on TTh [20/353 men
(5.7%)]. Table 2 shows that in men given TTh, HCT
was significantly higher ( p = 0.021, rank-sum test) in
men alive [median (IQR): 49.0 (48.0, 50.0)%] than in
those who died [median (IQR): 49.0 (48.0, 49.0)%].
Table 2 also shows that age, diastolic BP, and TC at
final assessment were significantly higher, whereas
TT was lower in the men who died. Accordingly, the
association between HCT (baseline and D) and mortal-
ity was confirmed with logistic regression analyses after
adjusting for the mentioned confounding variables
(Table 3: Model 1). Importantly, Table 2 shows that
Hb was not associated with mortality and was not in-
cluded as a confounding variable in the logistic regres-
sion analyses described in Table 3. Both baseline HCT
and D HCT were inversely associated with mortality,
and age at final assessment (baseline age+follow-up)
was positively associated with mortality (Table 3:
Model 1). Serum TT, diastolic BP, and TC were not as-
sociated with mortality. Interestingly, higher baseline
HCT and greater D HCT were associated with lower
mortality and with similar odds ratios (ORs). Table 3
(Model 2) gives the logistic regression analyses with
baseline HCT, D HCT, and age at final assessment
as independent variables, with all three conferring
a significant association with mortality. We then
replaced baseline HCT and D HCT with its sum
(HCT at final assessment), and this, as expected from
the previous logistic regression models, remained sig-
nificantly associated with mortality (Table 3: Model
3). To further characterize the relationship between
Table 1. Baseline Data of Testosterone Therapy-Treated and Untreated Men, and Changes at Final Assessment
in Testosterone Therapy-Treated Men
Baseline Final assessment
Untreated TTh (TU) TTh (TU)
No. of men 384 353
p (intergroup) Change in values p (intragroup)
Median (IQR) Median (IQR) Median (IQR) (Baseline vs. final)
Follow-up (months) 114.0 (96, 126) 0.52 105.0 (78, 141)
Age (years) 64.0 (60.0, 67.0) <0.0001 60.0 (55.0, 64.0)
TT (nmol/l) (trough) 9.7 (9.4, 10.4) 0.079 10.1 (9.4, 10.7) 9.0 (7.6, 10.4) <0.0001
HCT (%) 46.0 (45.0, 47.0) <0.0001 44.0 (43.0, 46.0) 5.0 (3.0, 7.0) <0.0001
Hb (g/dL) 14.7 (14.3, 15.1) <0.0001 14.5 (14.1, 14.9) 0.5 (0.3, 0.7) <0.0001
WC (cm) 109.0 (102.5, 116.0) 0.022 108.0 (100.0, 114.0) 10.0 (13.0, 6.0) <0.0001
HbA1c (%) 5.4 (5.1, 7.7) <0.0001 8.2 (5.8, 8.9), n = 270 2.1 (3.2, 0.7) <0.0001
Systolic BP (mmHg) 137.5 (131.5, 154.0) <0.0001 158.0 (141.0, 167.0) 25.0 (37.0, 13.0) <0.0001
Diastolic BP (mmHg) 78.0 (75.0, 88.0) <0.0001 94.0 (83.0, 98.0) 17.0 (24, 9.0) <0.0001
TC (mmol/L) 6.5 (5.6, 7.4) <0.0001 7.7 (7.2, 8.6) 2.6 (3.3, 2.1) <0.0001
TG (mmol/L) 2.9 (2.6, 3.3) <0.0001 3.2 (2.8, 3.5) 0.1 (1.3, 0.6) <0.0001
Rank-sum and sign-rank nonparametric tests were carried out to determine differences between baseline data (intergroup: untreated vs. TTh) and
changes seen at final assessment in men on TTh (intragroup) respectively. No significant differences (chi square) were observed between the two
groups regarding T2DM (untreated: 42.7%, TTh: 41.9%, p = 0.83), smoking status (untreated: 36.8%, TTh: 38.2%, p = 0.69).
BP, blood pressure; Hb, hemoglobin; HCT, hematocrit; T2DM, type 2 diabetes; TC, total cholesterol; TG, triglyceride; TT, total testosterone; TTh, tes-
tosterone therapy; TU, testosterone undecanoate; WC, waist circumference.
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HCT at final assessment and mortality, we stratified the
cohort by the median HCT (49%) at final assessment
and found that men with HCT (50–52%) at final visit
were at lower risk of mortality (Table 3: Model 4)
than their counterparts (HCT: 46–49%). It was noted
that the median HCT at final assessment of 49% was
observed in a large proportion of men (n = 123),
hence a further logistic regression analysis (not
shown in Table 3) was carried out, adjusted for age at
final assessment and excluding these 123 men. Men
with HCT at final assessment of 50–52% (n = 122)
were once again associated with lower mortality (OR:
0.083, 95% CI: 0.010–0.69, p = 0.021) than their coun-
terparts with HCT at final assessment of 46–48%
(n = 108). Table 3 (footnote) provides the unadjusted
mortality rates by HCT at final assessment [46–48%
HCT: 8/108 (7.4%), 49% HCT: 11/123 (8.9%), 50–
52% HCT: 1/122 (0.8%)].
To graphically demonstrate the difference in survival
in men on TTh stratified by the median HCT at final
assessment, we plotted a Kaplan–Meier survival curve
(Fig. 3) based on a Cox regression analysis (Fig. 3 foot-
note: Model 2), which, like the previous logistic regres-
sion analyses, also demonstrated that men with final
FIG. 2. Change in HCT at fixed time points (12, 48, 72 and 96 months) in untreated and TTh groups. HCT,
hematocrit; TTh, testosterone therapy.
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assessment HCT >49% were at lower risk of mortality
(Fig. 3 footnote: Model 1), even when adjusted for age
at final assessment.
Although this article is mainly focused on men given
TTh, we also present data on the association between
HCT at final assessment and mortality in 384 men opt-
ing against TTh. At final assessment, HCT was signif-
icantly higher ( p = 0.0001, rank-sum test) in men
alive [median (IQR): 46.0 (45.0, 47.0)%, n = 310] than
in those deceased [median (IQR): 45.0 (44.0, 46.0)%,
n = 74]. However, a logistic regression analysis revealed
that HCT at final assessment was not associated with
mortality (OR: 0.92, 95% CI: 0.81–1.04, p = 0.20)
when adjusting for the confounding variables (TT,
WC, HbA1c, BP, and lipid values) at final assessment.
This was the case when baseline HCT (OR: 0.88, 95%
CI: 0.68–1.14, p = 0.32) and D HCT (OR: 0.92, 95%
CI: 0.81–1.05, p = 0.23) were substituted for HCT at
final assessment as independent variables.
Discussion
Increased HCT is a common consequence of TTh and
clinical guidelines set action thresholds for discontinu-
ing treatment that are not based on clear outcome ev-
idence.4,22–26 Longitudinal studies suggest that HCT
influences CVD morbidity and mortality, although
the association may not be linear. We used an ongoing
registry database to demonstrate the pattern of D HCT
associated with TTh, and study putative associations
with all-cause mortality. Although HCT was not signif-
icantly changed in men not prescribed TTh, it was sig-
nificantly higher (median: +5.0%) in men on TTh at the
end of follow-up. Increased values were observed at 12,
48, 72, and 96 months after TTh compared with base-
line, although most of the increase was evident before
48 months (Fig. 2). Down-titrating/discontinuing TU
was not required as HCT did not exceed 52% in the
353 men given TTh.
It is tempting to state that the TTh-associated in-
crease in HCT could be a reversal of low HCT values
associated with low testosterone in adult-onset TD.
However, the distribution of baseline values in both un-
treated (mean HCT: 45.8%, 95% distribution: 44–48%)
and treated men (mean: 43.8%, 95% distribution: 37–
47%) was within the reference range (38.3–48.6%)
for males quoted by the Mayo Clinic.43 Furthermore,
HCT at final assessment in men on TTh (mean:
49.1%, 95% distribution: 47–51%) appears higher
than the Mayo Clinic reference range (only 30.6% of
Table 2. Comparison of Variables at Final Assessment
in Men Given Testosterone Therapy, Stratified by Mortality
Men on TTh (n = 353)
Alive Dead






59.0 (55.0, 63.0) 66.0 (62.0, 68.0) 0.0001
Follow-up
(months)
102.0 (78.0, 141.0) 130.5 (94.5, 135.0) 0.35
Data at final assessment
HCT (%) 49.0 (48.0, 50.0) 49.0 (48.0, 49.0) 0.021
Hb (g/dL) 14.9 (14.7, 15.3) 15.0 (14.7, 15.3) 0.89
Age (years) 68.5 (64.0, 71.5) 77.5 (69.3, 78.8) <0.0001
TT (nmol/L) 19.1 (17.7, 19.8) 17.9 (16.8, 18.7) 0.0050
WC (cm) 97.0 (94.0, 101.0) 98.5 (93.5, 103.0) 0.66
HbA1c (%)
(n = 269)





130.0 (126.0, 135.0) 0.12
Diastolic BP
(mmHg)
75.0 (73.0, 77.0) 77.0 (74.0, 82.0) 0.017
TC (mmol/L) 5.2 (4.9, 5.4) 5.3 (5.1, 5.4) 0.019
TG (mmol/L) 2.2 (2.1, 2.3) 2.2 (2.1, 2.2) 0.99
Intragroup differences were determined using rank-sum nonparamet-
ric tests.
Table 3. Logistic Regression Analyses Studying
the Association Between Baseline Hematocrit, D Hematocrit,
Hematocrit at Final Assessment, and Mortality, the Analyses
Adjusted for Confounders (Factors Significantly Associated
with Mortality in Table 2) in Men on Testosterone Therapy
OR (95% CI) p
Model 1
Baseline HCT 0.50 (0.31–0.79) 0.004
D HCT 0.55 (0.35–0.88) 0.012
Age at final assessment (years) 1.26 (1.13–1.41) <0.001
TT at final assessment (nmol/L) 0.88 (0.74–1.04) 0.13
Diastolic BP at final assessment (mmHg) 1.07 (0.95–1.21) 0.24




Baseline HCT 0.49 (0.31–0.79) 0.003
D HCT 0.54 (0.34–0.86) 0.009
Age at final assessment (years) 1.26 (1.13–1.40) <0.001
Model 3
HCT at final assessment 0.53 (0.33–0.83) 0.006
Age at final assessment (years) 1.27 (1.14–1.41) <0.001
Model 4 (factorized HCT)
HCT at final assessment >49 (50–52)% 0.091 (0.012–0.70) 0.006
HCT at final assessment £49 (46–49)% reference
Age at final assessment (years) 1.27 (1.14–1.41) <0.001
Adding T2DM into the regression models did not change the associ-
ation between HCT indices, age, and mortality. Unadjusted mortality
rates by HCT at final assessment (median: 49%). HCT (46–48%): mortali-
ty = 8/108 (7.4%), HCT (49%): mortality = 11/123 (8.9%), HCT (50–52%):
mortality = 1/122 (0.8%).
ORs, odds ratios.
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men having values within this distribution). Thus, it is
unlikely to be a return to higher normal levels from a
previously low level associated with TD, unless the
quoted reference range is subject to a lowering of values
due to a high proportion of men with adult-onset TD
(prevalence considered to be 6–12%).4
Baseline and D HCT were inversely associated with
mortality in men on TTh with similar ORs, indepen-
dent of age, serum TT, WC, HbA1c, BP, and lipids.
The greater the baseline value and increase in HCT
after TTh, the lower the risk of mortality. This associ-
ation remained evident when HCT at final assessment
(as a continuous variable and stratified by median value
and used in a logistic regression model as a factorized
variable) was substituted for baseline and D HCT.
Our data suggest that mortality risk reduction is evi-
dent with an upper end of HCT distribution at 52%
(50–52%) compared with a lower HCT (46–49%);
thus, we recommend the HCT action threshold re-
mains at 54% in well-hydrated men as dehydration can
raise HCT.44 At this moment, HCT could be consid-
ered a marker associated with mortality risk. Oxygen
content in the blood is related linearly to HCT and in-
creased HCT could plausibly increase tissue oxygena-
tion.45,46 However, increased HCT will exponentially
increase blood viscosity, thereby potentially reducing
FIG. 3. Kaplan-Meier survival curves of men on TTh, stratified by the median HCT at final assessment.
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blood flow.47,48 Thus, an ideal HCT should allow opti-
mized tissue oxygenation and blood flow, adding cre-
dence to the concept of a U- or J-shaped association
between HCT and morbidity/mortality.19,31,32 We did
not observe a U- or J-shaped association with mortal-
ity, with the upper limit of the HCT distribution in
our cohort reaching 52%, the inverse association
appeared to continue to this point.
HCT at final assessment was not related with mor-
tality in men not given TTh, when adjusted for other
confounding variables. Hence, our focus remained
with men on TTh. Interestingly, although many of
the metabolic risk factors such as WC, HbA1c, BP,
and TC were significantly decreased in men on TTh
(Table 1), they were not related to intragroup mortality
(Table 2).
The clinical impact of TTh-associated elevated
HCT is currently in focus after the 24-month T4DM
randomized controlled trial, which showed that TU/
lifestyle measures (504 obese/overweight men aged
50–74 years with impaired glucose tolerance or newly
diagnosed T2DM) were associated with significantly
lower glucose values, compared with 503 men on
placebo/lifestyle measures.49 In contrast to our study
where no man was seen to have an HCT >52%, 22%
(106 men) of the men on TU had at least a single
HCT ‡54% compared with 1% (6 men) treated with
placebo, although it is emphasized that TU was discon-
tinued in only 23 men due to two HCT values ‡54%.49
This longitudinal registry study has strengths and
weaknesses. Treatment compliance was not an issue
as TU was administered in clinic. Follow-up was long
and we had an almost complete data set (except
HbA1c). The nature of the study resulted in patients
not being randomized into TTh-treated and untreated
groups and differences in baseline factors were evident.
To counter this, most of the analyses describe intra-
group comparisons. Furthermore, our analyses using
mortality as the outcome centered on the TTh group
as D HCT only significantly changed in this cohort
(Table 1), hence the disparity of risk factor levels be-
tween the two groups was not an issue. The results
obtained were not affected when the cohort was strat-
ified by T2DM (Tables 1 and 3).
Conclusions
Our study, characterizing increase in HCT associated
with TTh, shows a median increase in HCT of 5.0%,
mostly occurring in the initial 48 months of treat-
ment. Our data show that benefit in mortality ex-
tended to HCT values of 52%, the HCT distribution
did not allow us to extend this value further.
Although it is premature to speculate whether the
change in HCT is causative or a surrogate affecting
the association between TTh and mortality, the data
indicate current guidance suggesting only HCT
>54% should trigger changes in TTh treatment, ap-
pears reasonable.4
Randomized controlled trials are needed to further
investigate our findings regarding entry and exit
thresholds and also on the association between HCT
and mortality to evaluate a possible causative role
using the current modified versions of the Bradford
Hill criteria.50,51
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